---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000061"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-08-12T20:15:35+00:00"
generated_at: "2026-08-12T20:17:31.014482+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma reports Q2 2026 cash $3.4M, completes $15.3M offering, FDA Type 2b expected

## Summary
- Q2 2026 cash and equivalents $3.4M as of June 30, 2026; excludes ~$13.6M net proceeds from July public offering.
- Completed $15.3M underwritten offering in July 2026; milestone warrants could add $34.0M gross; cash runway into Q1 2027.
- FDA BPD Type 2a meeting in Q1 2026 supported ABP-450 analytical approach; Type 2b feedback expected H2 2026.
- Regained NYSE American compliance on Aug 3, 2026.
- Presented comparability data at AAN (April) and AHS (June) meetings.

## SEC filing metadata
- accession: 0001837607-26-000061
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-08-12T20:15:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/0001837607-26-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000061
- JSON: https://secwatch.observer/filing/0001837607-26-000061.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.